Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

The vast majority of Roche’s oncology drugs with an orphan drug designation are expected to be blockbusters by 2025, including Perjeta (pertuzumab), Tecentriq (atezolizumab), Herceptin ...

For HER2-positive breast cancers, additions included pertuzumab, ado-trastuzumab emtansine, and neratinib. The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR ...

Background and Aims: Neuropathy in association with chronic liver disease, including cirrhosis, is recognized; however, there are differences in the incidence and type of neuropathy reported. The ...

The rising trend in health and lifestyle related problems in the world warrants us to be well informed and health-conscious of the latest happenings in this field. Medindia offers a freely ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).